India's pharmaceutical sector is showing two distinct paths. CDMOs are reporting strong quarterly growth, while major exporters to the US face ongoing pricing pressure and new, long-term tariff risks. Investors are now tracking how companies adjust their strategies to navigate these changing global policies.
The Indian pharmaceutical sector is witnessing a major shift as growth patterns diverge between two key business models. Contract Development and Manufacturing Organizations (CDMOs), which handle drug manufacturing for global clients, are showing strong momentum. In contrast, large drug manufacturers that rely heavily on exporting finished medicines to the United States are facing complex challenges ranging from pricing pressure to new regulatory risks.
CDMOs Lead with Strong Results
Recent financial results for the June quarter highlight the strength of the CDMO segment. Companies focusing on custom synthesis and manufacturing for global partners have reported significant earnings growth. For instance, Divi's Laboratories saw its net profit rise by 66 percent year-on-year, supported by demand in peptide manufacturing and custom synthesis. Similarly, Laurus Labs reported that its net profit more than doubled, fueled by a 67 percent surge in its CDMO business revenue. Gland Pharma also posted a 47 percent year-on-year jump in net profit, benefiting from long-term global manufacturing agreements.
US Market and Regulatory Headwinds
While CDMOs are thriving, large finished-dosage manufacturers like Sun Pharma, Dr. Reddy's Laboratories, and Cipla are dealing with a more difficult environment in the US. These companies are battling increased competition, which forces them to lower prices to maintain market share, and supply chain complexities. Adding to these concerns is a newly outlined US tariff plan for generic drug imports.
This policy introduces a phased approach: it sets a two-year zero-tariff period starting August 1, 2026. However, the structure creates long-term uncertainty, with tariffs planned to jump to 100 percent in 2028 and 200 percent by 2029. This potential change in the trade environment has added to market volatility, with the Nifty Pharma index showing fluctuations as investors assess the potential long-term impact on export margins.
Strategic Shifts and Future Monitorables
To counter these challenges, major Indian pharma firms are shifting their strategy. Instead of relying solely on mass-market generic drugs, which face heavy price erosion in the US, companies are increasingly focusing on 'complex generics' and specialty drugs. These products are harder to manufacture and face less competition, which can protect profit margins.
For investors, the key monitorables will be how companies manage their US operations during the tariff transition period and whether their pivot toward specialty drugs can offset the pricing pressure in the generic segment. Additionally, keeping an eye on the sustainability of CDMO demand, especially in areas like GLP-1 and peptide drugs, will be important for assessing the sector's overall growth.